Syndax Pharmaceuticals Inc(SNDX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 10 at 7:30 PM ET (Korea 9/11 08:30)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -2.52 | Insider Own | 9.19% | Shs Outstand | 89.2M | Perf Week | -9.43% |
| Market Cap | 1.68B | Forward P/E | - | EPS next Y | 59.84% | Insider Trans | -1.27% | Shs Float | 81.1M | Perf Month | -7.24% |
| Enterprise Value | 1.72B | PEG | - | EPS next Q | -0.47 | Inst Own | 114.93% | Short Float | 28.24% | Perf Quarter | 7.05% |
| Income | -0.22B | P/S | 6.66 | EPS this Y | 39.83% | Inst Trans | 10.8% | Short Ratio | 13.71 | Perf Half Y | -23% |
| Sales | 0.25B | P/B | 111.12 | EPS next 5Y | - | ROA | -33.97% | Short Interest | 22.90M | Perf YTD | -10.42% |
| Book/sh | 0.17 | P/C | 3.07 | EPS past 3/5Y | -10.26% -12.05% | ROE | -255.93% | 52W High | -26.46% ($25.59) | Perf Year | 19.64% |
| Cash/sh | 6.14 | P/FCF | - | Sales past 3/5Y | - 157.68% | ROIC | -36.55% | 52W Low | 44.88% ($12.99) | Perf 3Y | 7.54% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 35.43% | Gross Margin | 95.77% | Volatility(W/M) | 3.11% 3.86% | Perf 5Y | 2.84% |
| Dividend TTM | - | EV/Sales | 6.83 | Sales Y/Y TTM | 222.65% | Oper. Margin | -76.98% | ATR (14) | 0.85 | Perf 10Y | 40.66% |
| Dividend Ex-Date | - | Quick Ratio | 6.44 | EPS Q/Q | 33.35% | Profit Margin | -87.52% | RSI (14) | 39.16 | Recom | 1.08 |
| Dividend Gr. 3/5Y | - | Current Ratio | 6.77 | Sales Q/Q | 91.76% | SMA20 | -5.44% ($19.9) | Beta | 0.42 | Target Price | $37.55 |
| Payout | - | Debt/Eq | 39.03 | Earnings | 2026/8/4 | SMA50 | -9.6% ($20.82) | Rel Volume | 0.99 | Prev Close | $19.84 |
| Employees | 298 | LT Debt/Eq | 39 | EPS/Sales Surpr. | -22.85% -8.29% | SMA200 | -10.43% ($21.01) | Avg Volume(3M) | 1.67M | Price | $18.82 |
| IPO | 2016/3/3 | Option/Short | Yes/Yes | Trades | 15216 | Volume | 1,651,160 | Change | -5.14% |
Company
SNDX is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🧬 This is a U.S. biotech company that develops and commercializes therapeutics for cancer and immune-related diseases. It has commercialized treatments targeting blood cancers such as leukemia, as well as immune conditions related to transplantation, and is developing pipeline candidates with differentiated mechanisms of action. Combining its commercial products with its oncology and immunology pipeline, the company is a biotech building a foothold in underserved disease markets.
Over the past 1 year, roughly in the middle
26% below its 1-year high.
SNDX has weak earning power
Review management risk carefully before investing
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +39.8% this year.
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Long-term returns are close to the market
Would have changed by +7.5% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Short interest is a burden
Institutions hold 114.9%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
BBP 0.02%
CANC 0.01%
PTH 0.01%
XBI 0.01%
SGRW 0.01%It ranks #4 in the industry
Based on market cap of $2B.
SNDX $2B PER -
VRTX $130B PER 29.9
REGN $82B PER 19.6
ARGX $62B PER 37.5
FAQ
What kind of company is SNDX?
SNDX belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of SNDX?
The market cap of SNDX is approximately $1.7B, ranking 2,253 within its sector.
What is the 52-week high and low for SNDX?
SNDX has recorded a 52-week high of $25.59 and a low of $12.99.
